Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW Struggling to Set Date for Chuikyo Subcommittee Discussions on Opdivo
November 2, 2016
- MHLW Panel Backs Ono’s Hyperparathyroidism Drug Etelcalcetide
November 1, 2016
- PMDA Had 71 Individual Interviews in Regulatory Strategy Consultation Services in April-September 2016
November 1, 2016
- Inisync, 4 Other DPP-4 Inhibitors Under PMDA Risk Review
October 31, 2016
- Postponed PAFSC 2nd Committee Meeting Set for November 11
October 31, 2016
- MID-NET Working Group Discusses Access Fee Calculations
October 28, 2016
- Long-Listed Drug Use by Welfare Recipients Should Require Copay: MOF
October 28, 2016
- Panel Negative about Singling Out OTC-Switched Rx for Health Coverage Talks, Calls for Broader Discussions
October 27, 2016
- Shiozaki Does Not Rule Out Price Cut of Over 25% for Opdivo
October 27, 2016
- MHLW Alerts on Risk of Fulminant Type 1 Diabetes for Keytruda
October 25, 2016
- Pharma Groups Tender Requests to LDP on FY2017 Budget, Tax Reform
October 24, 2016
- Govt Panel Members Call for Drastic Drug Pricing Reform, Annual Revision
October 24, 2016
- Keytruda’s November Listing Skip Likely amid Opdivo Re-Pricing Fuss
October 24, 2016
- New Govt Panel Holds 1st Meeting for Healthcare, Long-Term Care
October 21, 2016
- MHLW Panel to Discuss Health Coverage of Ethical Drugs with OTC Versions on Oct. 26
October 21, 2016
- Oct. 27 MHLW Panel Meeting Postponed Due to Lack of Quorum
October 21, 2016
- Basic Policy on JP 18th Edition Calls for Expansion of Sections Related to Biopharmaceuticals: MHLW
October 21, 2016
- Heads of Medicines Regulatory Agencies to Hold Summit in Kyoto Next October
October 20, 2016
- Shiozaki Asks for Early Enactment of Clinical Research Bill
October 20, 2016
- MHLW Task Force Calls for Consolidation in Vaccines, Blood Products Industries; “Fundamental to National Security”: Minister
October 20, 2016
ページ
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…